Drugs / PE0139
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01835730 | Apr 2013 → May 2014 | type 2 diabetes mellitus | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02581657 | Oct 2015 → Nov 2016 | type 2 diabetes mellitus | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PE0139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01835730 ↗ |
| Route | Subcutaneous | “Single subcutaneous injection of PE0139, 40 mg/mL” NCT01835730 ↗ |